Dechra Pharmaceuticals PLC
LSE:DPH
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Zoetis Inc
NYSE:ZTS
|
54.9B USD |
Loading...
|
|
| DE |
|
Bayer AG
XETRA:BAYN
|
43.4B EUR |
Loading...
|
|
| US |
|
Elanco Animal Health Inc
NYSE:ELAN
|
12.4B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Dechra Pharmaceuticals PLC
Glance View
Dechra Pharmaceuticals PLC has carved out its niche in the veterinary pharmaceuticals industry, focusing on animal health, which is a sector often less spotlighted than its human counterpart but equally vital. Established in 1997 and headquartered in Northwich, Cheshire, England, Dechra has steadily made a name for itself as a formidable player addressing veterinary needs through innovative solutions and a dedication to expanding its product range. This company has built its empire by developing, manufacturing, and selling high-quality products that cater to the health of both companion animals, such as dogs and cats, and livestock. They have embedded themselves deeply into the global market, with a presence in countries across Europe, North America, and other regions, addressing therapeutic areas like endocrinology, dermatology, and anesthetics. A significant proportion of Dechra’s revenue comes through their strong partnerships and customer base spread across various veterinary practices and pet owners who rely on their trusted brands like Vetoryl and Felimazole. The company’s business model is finely tuned with a blend of regular product launches and strategic acquisitions, creating a comprehensive portfolio that keeps them ahead in the innovation curve. Not only do they supply medicine, but Dechra also invests heavily in research and development to ensure their offerings remain at the forefront of veterinary medicine. Through this, they balance between organic growth and strategic acquisitions, effectively broadening their impact in the field. This approach has not only propelled their financial success but also underscored their commitment to enhancing the welfare of animals globally.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Dechra Pharmaceuticals PLC is 0%, which is in line with its 3-year median of 0%.
Over the last 3 years, Dechra Pharmaceuticals PLC’s Net Margin has decreased from 0.1% to 0%. During this period, it reached a low of 0% on Jun 30, 2023 and a high of 7.8% on Dec 1, 2020.